Diabetic Foot Ulcers Treatment Market Analysis & Forecast: 2025-2032

Diabetic Foot Ulcers Treatment Market is estimated to be valued at USD 9.38 Bn in 2025 and is expected to reach USD 18.51 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 10.2% from 2025 to 2032.

Analysts’ Views on Global Diabetic Foot Ulcers Treatment Market:

The approach to diabetic foot management varies in primary and secondary healthcare. However, physicians are effectively using diagnostic tools to assess the nature and severity of diabetic. Physicians who were trained in the management of diabetic foot have reportedly been able to manage their patients better initially, with a good success rate. A unified approach for foot-care management may be achieved through diabetes foot education programs and the provision of national foot-care guidelines.

Figure 1. Global Diabetic Foot Ulcers Treatment Market Share (%), By Product, 2025

To learn more about this report, Request sample copy

Global Diabetic Foot Ulcers Treatment Market– Drivers

• Increasing incidence of diabetic foot ulcers: The incidence of diabetic foot ulcers is approximately 1500 per 100,000 diabetic individuals worldwide. Among U.S. veterans, the incidence of active diabetic foot ulcers is approximately 500 per 100,000 individuals. On the other hand, the incidence of active diabetic foot ulcers in the U.K. has been estimated at 220 per 100,000 individuals. Furthermore, its prevalence has been reported at 170 per 100,000 individuals among the United Kingdom population. The 5-year risk of mortality in diabetic patients with a foot ulcer is 2.5 times higher than in diabetic individuals without a foot ulcer.

Figure 2. Global Diabetic Foot Ulcers Treatment Market Share (%), By Region, 2025

To learn more about this report, Request sample copy

Global Diabetic Foot Ulcers Treatment Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global diabetic foot ulcers treatment market over the forecast period. North America is estimated to hold 39.9% of the market share in 2025. The global diabetic foot ulcers treatment market is expected to witness significant growth in the coming years, driven by the high prevalence of diabetic foot ulcers. Approximately 2 million Americans develop diabetic foot ulcers each year. Within 5 years of ulceration, over 50% die, and 5% lose a limb. Diabetic foot ulcers cost the U.S. healthcare system US$ 130 billion annually, require significant patient self-management in terms of daily wound care and ambulation restrictions, and can result in devastating function impacts if a major (above- or below-knee) amputation is required. Patients often fear major amputation from diabetic foot ulcers more than death.

Global Diabetic Foot Ulcers Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

• Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
• COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, are facing problems with the transportation of things from one place to another.
• However, the COVID-19 pandemic had a negative impact on the global diabetic foot ulcers treatment market, owing to a reduction in bed and operating room capacity, which further led to considerable delays in urgent and semi-elective surgical interventions. According to an American College of Surgeons (ACS) 2021 report, the nature of surgery and anesthesia practices changed during the COVID-19 pandemic as the most elective and non-urgent cases were postponed. 

Global Diabetic Foot Ulcers Treatment Market Segmentation:

The global diabetic foot ulcers treatment market report is segmented by product, by application, by end user, and by region.

• By Product, the market is segmented into advance wound dressings, skin substitutes, growth factors, negative pressure wound therapy devices, and other devices. Out of which, advanced wound dressings are expected to hold a dominant position in the global diabetic foot ulcers treatment market during the forecast period, and this is attributed to the increasing launch of advanced wound dressing-related products.
• By Ulcer Type, the market is segmented into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. Out of which, neuropathic ulcers is expected to dominate the market over the forecast period, and this is attributed to the increasing patient compliance with neuropathic ulcers.
• By End User, the market is segmented into hospital, specialty clinics, long term care centers, and ambulatory surgical centers. Out of which, hospital is expected to dominate the market over the forecast period, and this is attributed to the prompt treatment that can lead to proper recovery.

Among all the segmentation, the product segment is expected to dominate the market over the forecast period, and this is attributed to increasing launch of diabetic foot ulcers treatment related products.

Global Diabetic Foot Ulcers Treatment Market- Cross Sectional Analysis:

Key players are focusing on diabetic foot ulcers treatment with the new approval of the trials, which is expected to boost demand for the diabetic foot ulcers treatment market in the North America region. For instance, in November 2021, Paracrine, Inc., a biopharmaceutical company, announced that the U.S. FDA has granted full approval of its Investigational Device Exemption (IDE) to conduct a new pivotal trial titled Adipose Derived Regenerative Cells (ADRCs) in the Treatment of Diabetic Foot Ulcers (DFUs): A Prospective, Double-blind, Multi-center, Randomized, Parallel-Group Study –The “ASCEND Trial.”.

Global Diabetic Foot Ulcers Treatment Market: Key Developments

In June 2023, VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatments, announced that the Centers for Medicare and Medicaid Services (CMS) had assigned a Q-code for its CYGNUS Dual amniotic allograft product. The providers can begin using the CYGNUS Dual code Q4282 under the Healthcare Common Procedure Coding System (HCPCS). The CYGNUS dual product will become more readily available to patients who can use it, especially those with chronic wounds, diabetic foot ulcers, and other difficult-to-heal wounds, thanks to the HCPCS Q-code.

For instance, in May 2022, PolarityTE, Inc., a biotechnology company, announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers (DFUs), entitled “Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE,” or “COVER DFUs.”

Global Diabetic Foot Ulcers Treatment Market: Key Trends

New diabetic foot ulcers treatment clinics

The new clinics provide specialized care and advanced treatment options for patients with diabetic foot ulcers, improving their overall quality of life. Additionally, the increasing prevalence of diabetes worldwide has contributed to the growing demand for diabetic foot ulcer treatments and, subsequently, the expansion of the market. For instance, on August 19, 2023, Apollo Hospitals Group announced the launch of Apollo Diabetic Foot Clinics to provide preventive and therapeutic care in the treatment of the diabetic foot. The specialized clinics would help in the early identification of signs of a diabetic foot and prevent complications through proper diabetes management. The major aim would be to reduce the risk of ulcers, infections, and lower limb amputations due to infections arising from diabetes.

Global Diabetic Foot Ulcers Treatment Market: Restraint

The Lack of self-awareness towards the disease management

The lack of self-care management, insufficient support, treatment-oriented approaches, and all clients’ insufficient access to these services are some of the problems that still exist in the care and management of diabetic foot ulcers. These challenges contribute to the high rates of complications and amputations associated with diabetic foot ulcers. Additionally, the limited education and awareness about preventive measures further exacerbate the problem, emphasizing the need for comprehensive and accessible healthcare services for individuals with diabetic foot ulcers.

Key players focusing on developing advanced products with safety and cost considerations, and raising awareness in the treatment is an effective approach to driving market growth over the forecast period.

Global Diabetic Foot Ulcers Treatment Market - Key Players

Major players operating in the global diabetic foot ulcers treatment market include 3M Healthcare, Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, Molnlycke Health Care AB, Alkem Laboratories Ltd., Healthium Medtech, Kerecis, Podimetrics, Carmell Corporation, Paracrine, Inc., VIVEX Biologics, Inc., and PolarityTE, Inc.

*Definition: A diabetic foot ulcer is an open sore or wound that occurs in approximately 15 percent of patients with diabetes and is commonly located on the bottom of the foot. Of those who develop a foot ulcer, six percent will be hospitalized due to infection or other ulcer-related complications. Diabetes is the leading cause of nontraumatic lower extremity amputations in the United States, and approximately 14 to 24 percent of patients with diabetes who develop a foot ulcer have an amputation. Research, however, has shown that the development of a foot ulcer is preventable.